Focused On-demand Library for Progressive ankylosis protein homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HCJ1

UPID:

ANKH_HUMAN

Alternative names:

Alternative UPACC:

Q9HCJ1; B2RCA7; B3KMG4; D3DTD4; Q9NQW2

Background:

The Progressive ankylosis protein homolog, encoded by the gene with accession number Q9HCJ1, plays a pivotal role in regulating intra- and extracellular levels of inorganic pyrophosphate (PPi), potentially acting as a PPi transporter. This regulation is crucial for maintaining the balance of mineralization processes in the body.

Therapeutic significance:

Given its involvement in Chondrocalcinosis 2 and Craniometaphyseal dysplasia, autosomal dominant, understanding the role of Progressive ankylosis protein homolog could open doors to potential therapeutic strategies for these conditions. Targeting the protein's function may offer new avenues for treating joint pain, arthritis, and bone dysplasias.